Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-15
2008-04-15
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S293000
Reexamination Certificate
active
11389797
ABSTRACT:
The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof.The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
REFERENCES:
patent: 5064833 (1991-11-01), Ife et al.
patent: 5457105 (1995-10-01), Barker
patent: 5580870 (1996-12-01), Barker et al.
patent: 5616582 (1997-04-01), Barker
patent: 6057326 (2000-05-01), Brasca et al.
patent: 6972288 (2005-12-01), Himmelsbach et al.
patent: 2006/0155125 (2006-07-01), Chen et al.
patent: WO 97/03069 (1997-01-01), None
patent: WO 00/51991 (2000-09-01), None
patent: WO 00/55141 (2000-09-01), None
Chen Ping
Gavai Ashvinikumar V.
Zhao Yufen
Bernhardt Emily
Bristol--Myers Squibb Company
Korsen Elliott
Truong Tamthom N
LandOfFree
ATP competitive kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ATP competitive kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ATP competitive kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3951766